Physician profile
William K Kellum
NPI 1073830055
$858.37
in general payments reported to CMS, 2019-2025
8 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $33.93 · 2020: $539 · 2021: $140 · 2022: $145.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $254.03 | 2020-2022 | |
| Janssen Pharmaceuticals, INC | $174.48 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $157.28 | 2020-2021 | |
| Acadia Pharmaceuticals INC | $117.21 | 2020-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $101.69 | 2022 | |
| Pfizer INC. | $22.49 | 2021 | |
| Neurocrine Biosciences, INC. | $18.54 | 2019 | |
| Novartis Pharmaceuticals Corporation | $12.65 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Kellum listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.